StemCell Therapy

PARIS--(BUSINESS WIRE)--Regulatory News:

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Company will participate in the following industry and investor conferences:

The Business of Rare Policy SummitSeptember 20, 2022 - Washington DC, USBernard Gilly, Co-Founder & Chief Executive Officer, will take part in a panel discussion entitled "Business of Rare: State of the Industry" at 11:15 am EDT / 5:15 pm CEST.

GenSight Biologics is a headline sponsor of the conference and will also host a reception entitled "A Rare Pairing" at 4:30 pm EDT / 10:30 pm CEST.

Chardan's 6th Annual Genetic Medicines ConferenceOctober 3 - 4, 2022 - New York, USBernard Gilly, Co-Founder & Chief Executive Officer, and Thomas Gidoin, Chief Financial Officer, will attend in person on October 4, 2022, present in a fireside chat at 2.30 pm EDT / 8.30 pm CEST, and host investor meetings.

The fireside chat will be webcast live and in replay using this link.

4th Annual HealthTech Innovation Days (HTID) 2022October 13 - 14, 2022 - Paris, France & VirtualBernard Gilly, Co-Founder & Chief Executive Officer, and Thomas Gidoin, Chief Financial Officer, will attend in person and host investor meetings.

BTIG Ophthalmology Day 2022November 29, 2022 - VirtualBernard Gilly, Co-Founder & Chief Executive Officer, and Thomas Gidoin, Chief Financial Officer, will participate and host investor meetings.

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics lead product candidate, LUMEVOQ (GS010; lenadogene nolparvovec), is an investigational compound and has not been registered in any country at this stage; a marketing authorization application is currently under review by the EMA for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.

About LUMEVOQ (GS010; lenadogene nolparvovec)

LUMEVOQ (GS010; lenadogene nolparvovec) targets Leber Hereditary Optic Neuropathy (LHON) by leveraging a mitochondrial targeting sequence (MTS) proprietary technology platform, arising from research conducted at the Institut de la Vision in Paris, which, when associated with the gene of interest, allows the platform to specifically address defects inside the mitochondria using an AAV vector (Adeno-Associated Virus). The gene of interest is transferred into the cell to be expressed and produces the functional protein, which will then be shuttled to the mitochondria through specific nucleotidic sequences in order to restore the missing or deficient mitochondrial function. LUMEVOQ was accepted as the invented name for GS010 (lenadogene nolparvovec) by the European Medicines Agency (EMA) in October 2018. LUMEVOQ (GS010; lenadogene nolparvovec), is an investigational compound and has not been registered in any country at this stage; a marketing authorization application is currently under review by the EMA.

Originally posted here:
GenSight Biologics to Present at Upcoming Industry and Investor Conferences - Business Wire

This entry was posted on September 20, 2022 at 2:08 am and is filed under Blindness. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |